Ontwikkeling van een confirmatiemethode voor de detectie van recombinant bovine somatotropine in serum van melkvee. by Smits, Nathalie
Development of a confirmatory method for the detection of 
recombinant bovine somatotropin in serum of dairy cattle 
 
 
 
 
 
 
 
 
  
 
N.G.E. Smits 
2013 
Afstudeeronderzoek Masteropleiding Milieuwetenschappen, 
Faculteit Natuurwetenschappen, Open Universiteit 
 
2 
 
  
3 
 
Development of a confirmatory method for the detection of 
recombinant bovine somatotropin in serum of dairy cattle 
 
Ontwikkeling van een confirmatiemethode voor de detectie 
van recombinant bovine somatotropine in serum van 
melkvee 
 
 
 
 
 
 
 
 
 
 
 
 
 
Master thesis committee: 
OU afstudeercoördinator Drs. Pieter Geluk   pieter.geluk@ou.nl 
OU begeleider   Dr. Raymond Niesink   R.Niesink@tiscali.nl 
OU begeleider   Dr. Lily Fredrix   lily.fredrix@ou.nl 
RIKILT begeleider  Dr. Leen van Ginkel   leen.vanginkel@wur.nl 
 
 
The cover illustration shows a graphical abstract of the method. It presents rbST captured to the beads, its elution, 
cutted by trypsin and then measurement by LC-MS/MS. This is a graphical abstract of the workflow as presented in 
Figure 3.2 
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Abstract 
 
Administration of recombinant bovine somatotropin (rbST) enhances milk yield in 
dairy cattle. Use of rbST for this purpose is approved in several countries, however, 
prohibited in the European Union. To pinpoint rbST abuse confirmatory methods are 
required to confirm a positive screening result. Confirmatory analysis are a challenge 
due to the similarity of rbST with the endogenous hormone (bST), low concentrations 
of rbST in the blood circulation after administration and the short half-life of rbST. 
Moreover, the serum matrix, high abundant in proteins, interferes in LC-MS/MS 
methods by suppressing the rbST signal. If at all measurable, these methods are in 
need of high sample volumes in order to reach the necessary sensitivity. Therefore a 
novel approach of sample treatment, which overcomes these challenges, is 
presented in this study. A new magnetic bead based immunoaffinity step is 
developed for rbST capture from the serum prior to LC-MS/MS measurement. After 
the rbST capture step, the serum matrix is removed, therewith removing interfering 
proteins. RbST is then eluted from the beads and LC-MS/MS confirmation analysis is 
performed. This novel approach enables rbST measurements far below the required 
10 ng mL-1, necessary for effective control. Preliminary results of rbST 
measurements on a selection of serum samples from one rbST treated cow are 
presented. The data demonstrate that this novel approach is capable to identify rbST 
in serum from a treated cow from the 6th day after treatment onwards. 
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Samenvatting 
 
Door recombinant somatotropine (rbST) aan melkvee toe te dienen kan de 
melkproductie verhoogd worden. Dit is in verschillende landen toegestaan waaronder 
de USA, maar verboden in de Europese Unie. Om rbST misbruik aan te kunnen 
tonen zijn methoden voor de bevestiging van positieve screeningsresultaten nodig. 
Deze bevestiging van rbST is een uitdaging vanwege de overeenkomst met het 
endogene hormoon (bST), de lage rbST concentraties die na toediening in het bloed 
circuleren, de korte halfwaarde tijd en daarnaast signaal suppressie in de LC-MS/MS 
door storende eiwitten afkomstig van de complexe serum matrix. Om rbST met de 
benodigde gevoeligheid direct in serum te kunnen meten, zal daarom het monster 
volume groot moeten zijn. Om rbST gebruik te kunnen bevestigen wordt, in dit 
rapport, een nieuwe voorbewerkingsmethode  voor serum gepresenteerd. 
Voorafgaand aan LC-MS/MS wordt een, op magnetische beads gebaseerde 
immunoaffiniteits stap uitgevoerd om rbST uit het monster te binden en te 
concentreren. Na binding van het rbST aan de magnetische beads, wordt de serum 
matrix en de daarmee storende eiwitten verwijderd. Het rbST wordt vervolgens van 
de magnetische beads geëlueerd waarna confirmatie met LC-MS/MS plaats kan 
vinden. Deze nieuwe methode maakt het mogelijk om concentraties lager dan, de 
voor effectieve controle benodigde, 10 ng mL-1 te meten. Deze nieuwe methode is 
toegepast op een selectie van serum monsters van een met rbST behandelde koe, 
en de verkregen resultaten worden in dit rapport gepresenteerd. Deze data laten zien 
dat het met deze nieuwe methode mogelijk is om rbST in behandelde koeien vanaf 
de 6e dag na behandeling te meten.   
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1 Introduction 
 
Recombinant somatotropin (rbST) can be used to enhance milk yield and growth 
performance in cattle. Its use is licensed in several countries like for instance the 
USA, but banned in the European Union (Council Decision 1999/879/EC). Its 
possibility of misuse in the European Union can, however, not be excluded. This 
suspiciousness seems to be justified. During the writing of this report, in Spain, at 
around 300 farms, rbST containing syringes were found. This emphasises the need 
for a method for the detection and confirmation of the presence of rbST, to enforce 
the ban on its use. The development of such a method will be the aim of this study. 
For this study the following hypothesis was formulated: 
Using a magnetic bead based immunoaffinity purification step will enable detection 
and confirmation of rbST misuse in serum of rbST treated dairy cows. 
First this report will provide information about rbST itself. Therefore, in the theoretical 
section, different aspects of rbST will be pointed out. Metabolism and mode of action 
will be shown, followed by the history of rbST, from the first use of somatotropin to 
enhance growth and lactating performance till the availability of recombinant 
somatotropin. The use of rbST has impact in several fields like: environment, human 
and animal health and economic impact. These impacts will be highlighted 
separately. Relevant  legislation will be discussed  and accordingly the need to be 
able to confirm abuse of rbST. The theoretical part of this report will be followed by a 
practical part describing the development of a confirmatory method for pinpointing 
rbST abuse in serum of dairy cattle. This novel method combines two different 
expertise fields as it uses immunoaffinity which is classically used for screening 
purposes, and mass spectrometry, which normally is used for confirming the 
presence of specific compounds. In this report the strength of combining these two 
expertise fields is shown, implying its use in many fields where low concentrations of 
proteins in difficult matrixes need to be determined, like for instance in toxicology and 
health, but also for measurements in the environmental field. Finally, 
recommendations will be described for future focus.  
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2 Theory 
 
2.1 Somatotropin; mode of action and metabolism 
 
Somatotropin (ST), also known as growth hormone (GH), is a single-chain 
polypeptide hormone which controls differentiation, growth and metabolism of many 
cell types of vertebrate species (Baumann, 2012). Therefore, it plays an important 
role in the control of growth and reproduction. It is a hormone produced by the 
anterior pituitary gland and belongs to the same hormonal family as prolactin and 
placental lactogen (Secchi & Borromeo, 1997). One of its characteristics, in 
combination with other compounds, is stimulation of mammary gland growth and 
regulation of milk production (Svennersten-Sjaunja & Olsson, 2005). ST is secreted 
in a pulsatile fashion. When secreted into the blood it binds to Growth Hormone 
Binding Protein (GHBP), enabling transportation (Baumann, 2012) towards multiple 
target organs. The liver for example is stimulated by ST for production of Insulin like 
growth factor -1 (IGF-1), IGF-1’s binding protein Insulin like growth factor binding 
protein 3 (IGFBP3) and acid labile subunit (ALS) (Duntas & Popovic, 2013). These 
proteins are then excreted into the blood separately, but also as an IGF1-IGFBP3-
ALS complex. Within the bloodstream IGF-1 has apoptotic properties and moreover, 
plays a role in the differentiation and proliferation of cells (Crowe et al., 2009). 
Another function of ST is the increase of for instance type 3 procollagen (P-III-NP) 
and osteocalcin, proteins enhancing bone and collagen strength. Furthermore, ST 
has anabolic, lipolytic and post-trauma healing properties therewith increasing lean 
body mass and decreasing fat mass (Duntas et al., 2013). The release of ST is 
controlled by multiple mechanisms. The hypothalamus regulates ST release through 
growth hormone releasing hormone (GHRH) for stimulation of ST release and 
somatostatin for inhibition for release of ST. Moreover, two control feedback loops of 
ST and circulating related proteins can be differentiated in controlling ST excretion. A 
short auto-feedback loop in which ST itself inhibits its own secretion and a long 
feedback loop mediated by IGF-1 where high levels of IGF-1 influence both 
hypothalamus and the anterior pituitary for reduction of ST secretion (Baumann, 
2012). In Figure 2.1 a schematic representation of ST and its metabolism is shown. 
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Figure 2.1: Schematic representation of the hypothalamic-pituitary-peripheral GH-
axis. (-) denote inhibitory action, (+) denotes stimulatory action, - - - indicates direct 
(non-IGFI-mediated) GH action on tissues [Reproduced from Baumann (2012)]. 
 
As ST stimulates the mammary gland growth and milk production, exogenous 
administered ST will stimulate this production even more. The average daily milk 
yield of dairy cows in the EU-15 (appendix I) calculated from 286.576 milk specialized 
farms in 2008 was 19,2 kg day-1 (European Commission, 2011). According to Elanco, 
producer of recombinant bovine ST (rbST) an increase of milk yield of 4,5 kg day-1 
should be established by the use of their slow release formulae of rbST (Elanco, 
2012). This is confirmed in literature where increases of 3,61 kg day-1 (Mishra, 
Mahapatra & Shukla, 2011), 4,5 kg day-1 (Capper & Bauman, 2013) were described. 
This is, however an average milk yield increase. Results per dairy farm strongly 
depend on good farm practices.  
Next to ST, several other factors can influence milk yield.  Mellado et al. (2011) 
showed that lactation number is of influence, as milk production increases with 
lactation number. This is maximized at the fourth and fifth lactation, with no significant 
decrease for further lactation numbers. This phenomenon is explained by an 
increasing size and development of the udder, consequently increasing the number 
of secretory cells. Furthermore, also season of calving is described as influencing 
milk yield. Where cows are induced to lactation in the hotter seasons of the year, i.e. 
the spring and summer, milk yields are significantly lower than inducing lactation in 
autumn and winter. Moreover, the length of the dry period also effects the milk yield, 
a dry period of at least 45-50 days is recommended (Lactation resource library, n.d.), 
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Klusmeyer et al. (2009) however, showed a dry period of 32 days in combination with 
rbST use is most optimal in terms of milk yield before and after partition, but also 
showed the importance of a dry period in general. When past production data, based 
on traditional techniques, are compared with current production data, which are 
supported by highly advanced techniques , an increase in milk yield from an annual 
average milk yield per cow from 1 890 kg in 1924 to 9 682 kg in 2011 in the USA is 
observed. One of the contributors to this increase is rbST use, which is legally used 
in the United States (Capper et al., 2013). 
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2.2 History of rbST  
 
Increasing milk production has always been an issue. Since our food supply 
changed, from hunting and gathering our food by ourselves to agriculture, farmers 
were always keen on their best livestock. This included ensuring offspring would 
descent from the best livestock so positive features were inherited. The last century 
more technologies became available. The introduction of genetic selection tools and 
the potential to produce a large number of high-genetic merit offspring via artificial 
insemination have allowed dairy producers to make informed decisions on selection 
criteria for breeding cattle. In addition, in the 1930’s it was already discovered that so-
called “total preparations” from the anterior pituitary containing a whole number of the 
hypophysis hormones, increased milk production. Therefore, an animal experiment 
was initiated, wherein 510 cows were treated with this total preparation. They 
received an injection every 10 days, ten injections in total. Also 90 cows were 
selected as control cows. Within this animal experiment, the potential to increase milk 
production by using the “total preparation” was clearly shown. After 24 hours an 
increase in milk yield of approximately 22% was seen, peaking the second day with 
29% and then decreasing again till the control level after 10 days (Asimov & Krouze, 
1937). However, supply of this total extract was limited to anterior pituitary glands 
from slaughtered cows, and therefore only applicable on a small scale, to enable 
significant impact on milk yield (Bauman, 1999). This changed in the 1980’s when 
biotechnology offered the opportunity to produce rbST. Prior to that, the hormone 
responsible for this lactopoietic activity of the crude extract was determined in 1949 
as the growth hormone (Cotes, Crichton, Folley & Young, 1949), subsequently the 
structure was revealed in 1966 by Li, Liu & Dixon (1966). A joint cooperation between 
Monsanto Co. and Genetech Inc. then researched the possibility to produce rbST 
with biotechnological techniques (Bauman, 1999). This led to four commercialized 
proteins, chemically almost identical to the endogenous form, of 191 amino acids and 
approximately 22 kDa, with distinct N-terminal ends as shown in Figure 2.2. 
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Figure 2.2: Schematic representation of the bovine growth hormone molecule with 
the N-terminal end in detail with the alanine (A) replaced by methionine (M) as in 
Monsanto recombinant rbST [reproduced from Le Breton, Rocherau-Roulet, Pinel, 
Cesbron & Le Bizec (2009)], plus the N-terminal amino acid sequence of 
endogenous bST and four genetically engineered rbST’s (Secchi et al., 1997). The 
symbols used to address amino acids are listed in appendix II.   
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2.3 Environmental impact 
 
As the use of rbST changes milk yield, but also food intake and accordingly excretion 
products, impact for the environment most likely will change. The environmental 
impact is in general focussed on the greenhouse gas (GHG) emissions, also called 
carbon footprint. Therefore, GHG emission is used for pinpointing environmental 
impact, due to rbST use instead of the also important impact on water use, land and 
air-quality.  Global GHG emissions due to agriculture were estimated in the range of 
4 – 32 % of total GHG human made emissions. Although literature clearly disagrees 
on the exact number, there is agreement that livestock significantly contributes to the 
carbon footprint (Capper et al., 2013). To study the environmental impact due to 
rbST, a comparison in environmental impact between rbST treated and untreated 
cows is made. For this comparison, the accepted functional unit is the unit of food 
(kg,t). For dairy this translates to the mass of milk, which is refined to fat and protein 
content. Therefore, environmental impact comparison starts at nutrition as an 
important parameter. For every animal, a daily basis of nutrients is needed to support 
vital functions, health, and a minimum of activities. This is the so called maintenance 
requirement. Additional nutrients are needed to, for instance, support production, 
growth, pregnancy and lactation. The maintenance requirement is dependent upon 
bodyweight and does not change as a function of production. Therefore, 
improvement of feed efficiency and productivity, consequently reduces resource use 
and GHG emissions per functional unit (Capper et al., 2013). As mentioned before 
rbST increases milk yield with an average of 4.5 kg day-1 per cow. As feed intake isn’t 
increased proportional to this increase in milk yield rbST use reduces the amount of 
land required to produce a unit of milk by 9.2%. Moreover, water use is decreased by 
10.4% and the carbon footprint by 9.1% according to Capper et al. (2013). In popular 
terms; rbST supplementation of 1 million cows would reduce the dairy industry’s 
carbon footprint by the annual equivalent of removing approximately 400 000 cars 
from the road. Although production efficiency per region depends on more factors 
than rbST use, the graph obtained by Capper et al. (2013) as shown in Figure 2.3 
clearly shows the low carbon footprint in kg CO2-equivalents per kg milk in North 
America.  
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Figure 2.3: Average annual carbon footprint per unit of energy corrected milk across 
global regions. Data adapted from Capper et al. (2013) 
 
It however, also shows indirectly the influence of farm practices and environmental 
differences, like high temperatures. The impacts as described before however, can’t 
be subtracted from the figure. Although rbST is banned in Oceania and Europe, a 
relatively high production is still established with one of the lowest carbon footprints, 
while rbST use is legal in central and south America, the graph shows opposite 
results, very high carbon footprints without a high production. An explanation might 
be that the total milk production of an area is taken into account. As in North America 
in 2002, 22,3 % of the dairy cows were treated with rbST (Losinger, 2007), only these 
cows will  contribute to lowering the carbon footprint. Moreover, as total regions are 
taken into account in this figure, it is difficult to pinpoint exactly the areas with 
legalised rbST use. What however is clearly shown in the graph is that in western 
societies impact on carbon footprint is low. The high carbon footprints can be found in 
the less developed countries. This can have several reasons. The areas mentioned 
lie in high temperature regions, having low quality pastures and high incidence of 
disease and parasites. The total environment therefore, leads to unfavourable milk 
production (Jarvis, 2000) and consequently to a high carbon footprint.   
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2.4 Health impact 
 
2.4.1 Human health 
 
The impact of milk consumption from rbST treated animals to human health is under 
discussion for a long time already. When examining the milk itself, the gross 
composition of milk: the fat, protein and lactose content, isn’t altered during rbST 
treatment. Moreover, microconstituents of milk seem to be unchanged as well. 
However, attention is focussed on ST and IGF-1 content (Etherton & Bauman, 1998). 
Whereas bST content seems similar (Etherton et al., 1998), rbST is secreted into the 
milk in low concentrations. Expected concentrations are below 1 ng mL-1 (Le Breton 
et al., 2010). This rbST however, shouldn’t have a growth promoting function in 
humans. As when amino acid sequences of different species are compared by 
alignment, differences are clearly shown. Moreover, it is well-known that 
somatotropin has significant species specific characteristics and therefore should 
have no impact on humans (Secchi et al., 1997). The other protein however, IGF-1, is 
not species specific and data show that the average IGF-1 content in milk is 
increased significantly (Daxenberger, Sauerwein & Breier, 1998). Impact concerning 
this increase is still under discussion. Recent studies are consistent with the 
conclusion that high concentrations of IGF-1 in the blood circulation are associated 
with an increased risk for several cancers like premenopausal breast cancer, prostate 
cancer, lung cancer, colorectal cancer, endometrial cancer and bladder cancer 
(Samani, Yakar, LeRoith & Brodt, 2007). Moreover,  dairy product intake is positively 
associated with plasma IGF-1 levels (Ma et al., 2001). However, It is unclear whether 
these effects refer to IGF-1 intake in general which is present in all dairy products, or 
are due to additional IGF-1 intake.  
 
2.4.2 Animal health 
 
The commercial available rbST formulae from Elanco has a package insert which 
identifies possible adverse health effects for the animals. These effects include an 
increased risk of adverse reproductive effects, clinical mastitis, foot and leg problems, 
injection site reactions, udder edema, and “other general health effects” (Elanco, 
n.d.). As the chance on these side effects due to rbST use isn’t clear from this insert, 
the impact of rbST use on animal health was described in several papers, with 
different research goals and different outcomes. To be able to use these different 
studies and investigate the general trend Dohoo et al. (2003) combined information 
on animal health, reproductive performance, and culling (final removal of cows for 
several reasons) according to rbST use in a meta-analysis review. Therefore, 53 
manuscripts and reports were identified and used in this meta-analysis. From this 
information a total of 546 outcome parameter estimates from 94 groups of cows were 
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extracted and included in the database of production and health effects. The effects 
of rbST on udder health were divided into the effects on the frequency of clinical 
mastitis and the effects on subclinical mastitis. Results obtained show that rbST 
increased the risk of clinical mastitis with approximately 25%. Until now it is unknown 
whether this increase is due to the use of rbST itself or to the indirect effect of the 
increased milk production. According reproduction, parameters related to breeding 
and conception were evaluated. An increased risk of 40% of a cow failing to conceive 
was associated to rbST use. However, when conceived, there were no further 
consequences due to rbST use. Also lameness was examined, this was however 
difficult as the definition, diagnosis, and recording showed considerable variation. 
Therefore, in the meta-analysis, all causes of clinical lameness were combined and 
the risk due to rbST use was examined. It showed an increase of 50% in clinical 
lameness in rbST treated dairy cows (Dohoo et al. 2003). This meta-analysis clearly 
showed that the, according to Elanco’s side effects due to rbST use (Elanco, n.d.), 
are not incidents, but do effect high percentages of dairy cows treated with rbST. 
Furthermore, these elevated incidents of inflammation require treatment with 
antibiotics. This is a matter of concern as well, as this will promote antibiotic 
resistance, which will lead to difficulties in animal treatment, but eventually will lead to 
problems according to antibiotic resistance in human (Rodriguez-Rojas, Rodriguez-
Beltran, Couce & Bazquez, 2013).  
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2.5 Economic impact 
 
When looking at the information brochure from Elanco as shown in Figure 2.4, a 
surplus for producers is promoted. According to Elanco, after subtraction the total 
expenses from the increased income, Posilac increases the profit per cow per day 
with $0,62. The calculation is clearly shown in this information brochure and 
individual farmers 
are able to fill in their 
own circumstances. 
This information 
however, is 
estimated according 
to most optimal 
circumstances. It 
doesn’t take into 
account the likely 
decreasing milk 
prices due to overall 
increasing milk yield 
and the extra 
medical care needed 
due to rbST use. 
Also the milk loss 
when cows are 
treated with 
antibiotics isn’t taken 
into account. This 
leads to the farmers 
perception of 
acquiring a surplus. 
This can be 
explained by the 
cost-benefit balance. 
Looking at the cost-
benefit balance of 
rbST use, there are 
several economic 
forces and different stakeholders influencing this balance. To be able to truly 
compare cost-benefit, legal use of rbST is a prerequisite. Therefore, data from the 
USA are used as an example. When then simplifying the stakeholders to in total 
three parties, there is the Elanco company, trading rbST injectables within the USA, 
the farmers  producing the milk and the consumers demanding a certain amount of 
milk. Losinger (2007) looked into the economic forces between these three 
23 
 
stakeholders to obtain information about the benefits obtained by rbST use. 
Therefore, first a comparison of measurable quantities between 1996 and 2002 was 
made. This showed that the amount of dairy cows treated with rbST doubled within 
this period of time from 10,1% to 22,3% respectively. The number of dairy cows 
decreased with approximately 188 000, which is 2% of the 1996 amount. However, 
despite the decrease in number of dairy cows, the total quantity of milk produced 
increased with 7 billion kg, which is an additional 11% in comparison to the 1996 
yield. In this period the mean price of milk dropped from $ 0,328 per kg in 1996 to $ 
0,269 per kg in 2002. The increased production likely also influenced this market 
price.  Consequently, for the farmers a fragile balance occurs, where on the one hand 
there is a loss in economic surplus due to decreasing milk prices, while on the other 
hand economic surplus can be gained due to the increased output. The balance 
between these three stakeholders in time can be shown in a general economic graph 
as shown in Figure 2.5. 
 
Figure 2.5: Demand and supply for milk. Wherein S represents the supply curve for 
milk in the USA, when no rbST is used. S intersects with the demand for milk, to 
determine the quantity of milk produced (Q) and the market price (P). The use of 
rbST in dairy cows causes the quantity of milk produced to increase to Q’, the supply 
curve for milk to expand to S’, and, assuming no change in demand for milk, the 
market price to fall to P’ [Reproduced from Losinger, 2007]. 
 
This graph clearly shows the fragility of the balance. Demand and produced quantity 
should stay stable to retain the market price, and to be able to calculate profit like 
Elanco does in its brochure.  
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2.6 Legislation 
 
Worldwide legislation concerning rbST isn’t unanimous. Where Europe has a ban on 
rbST use since 2000, in the United States for instance it is common practice to use 
rbST for increasing milk production. This has to do with weighing the advantages 
over the disadvantages, but moreover also with public acceptance of its use. The 
process regarding the regulatory policy of the European Union evolved over the 
period of 1987 to 2000. Starting with the request from the companies Monsanto and 
Elanco, in accordance to the procedure laid down in Council Directive 87/22, for 
marketing authorization of their rbST based products. The Committee of Veterinary 
Medicinal Products (CVMP) assessed the quality, safety and efficiency of the rbST 
products and advised to authorize its use in the European Union as a medical 
product. Consequently, regulation of the rbST products should then be layed down 
under Council Regulation 2377/90, according veterinary medicinal products in 
foodstuffs of animal origin. The CVMP drawed a conclusion in 1993 and considered 
the use of rbST in dairy cattle as no risk for health of the consumers of milk and meat 
from treated animals, and moreover regarding animal health and welfare, it stated 
that there is no undue risk. Despite these findings prohibition of rbST use was 
extended, even though the European Court decided in favour of Elanco and 
Monsanto. Accordingly, the European Commission was obliged to include rbST 
under Annex II of Regulation 2377/90, which is reserved for substances that are not 
subject to a maximum residue limit (MRL).  As The Council however, indicated that 
further research was needed to determine the animal welfare effects, according to 
mastitis and metabolic disorders in dairy cattle. This led to a report prepared by the 
Scientific Committee on Animal Health and Welfare (SCAHAW) on animal welfare 
aspects, concluding that there is a substantial increase in levels of foot problems, 
mastitis and injection site reaction. Furthermore, in the press release IP/99/758 by 
the European Commission, it was also stated that “BST is not used in cattle for 
therapeutic purposes, but only to enhance milk production. Therefore it results from 
the opinion of the SCAHAW that BST should not be used in dairy cows”. This finally 
led to the ban of rbST from January 1st, 2000 according to Council Directive 
98/58/EC (Brinckman, 2000).  At the joint FAO/WHO food standards programme 
Codex Alimentarius Commission, the request for draft MRLs for bovine 
somatotropins is held at step 8 since the 23rd session of the commission in 1999. 
This year, 2013 however, the commission requested the codex secretariat to prepare 
a paper, including the history of the development and discussion of the MRLs in 
codex, to determine a possible MRL for rbST (Codex Alimentarius Commission, 
2012).  
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2.7 Consumer perception 
 
To be able to commercialize and sell milk from rbST treated cows, you need 
consumers to accept the product. Therefore, it is important to know what consumers 
perception is about rbST treatment for milk enhancement. A trend which is seen 
more and more among consumers in Western society is the awareness of product 
origin, adding high value to local products. Furthermore, also environmental pressure 
and food safety remain of importance. Next to these, also greater interest is 
expressed  by consumers in animal welfare and treatments.  Acceptance of products 
by consumers is often measured by a “willingness to pay” (WTP). By assessing this 
WTP it is noteworthy that the degree of processing is of importance. When products 
are processed more, and therefore are less associated with animal origin, treatment 
of the animals becomes of less importance, like for instance when WTP is assessed 
of milk versus icecream (Olynk & Ortega, 2013). Acceptance of products obtained by 
agricultural biotechnology is dependent on risk perception of the consumers. For 
rbST use in dairy cattle attitudinal factors, personal health factors and demographic 
factors were assessed. First, it is shown that among attitudinal factors, identification 
with animal rights groups increased significantly the perceived risk. Second, how 
personal health influenced risk perception  depends on the potential disease. 
Contrary to a personal or family history of cancer or heart disease, personal health 
concerns and lactose intolerance didn’t show a significant change in risk perception.  
Last, among demographic factors, in general females and Caucasians significantly 
perceived more risk. The presence of kids in the family, age and being poor, 
however, showed no significant impact on risk perception. Of importance to risk 
perception is also that the application of rbST doesn’t have a clear benefit to 
consumers. As current strategies of biotechnology companies are focussed on 
applications that affect farmers production costs, adoption of strategies developing 
clear benefits for consumers would raise consumers acceptance of biotechnology in 
agriculture. Moreover, labelling also contributes to risk perception. Labelling itself and 
availability of multiple types of milk, gave consumers choice options, which appears 
to have decreased perception of risk significantly, even if consumers didn’t act on it 
(Zepeda, Douthitt & You, 2003). Labelling.  however, is  under discussion, as it 
provides choice options for consumers, while for farmers labelling enables to 
differentiate their product, rbST-free and organic milk might stigmatize conventional 
milk, eventually leading to potentially reducing demand for all types of milk (Kanter, 
Messer & Kaiser, 2009). 
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2.8 Methods to control rbST ban 
 
The ban on rbST use does require methods to control this ban and therefore 
methods for the determination of rbST in food (products) are urgently needed. The 
detection of rbST abuse however, is complex due to the short half-life of rbST, the 
similarity with the endogenous hormone (bST) and the strong fluctuations of bST in 
serum. As rbST-dependent biomarkers have a longer half-life they offer a promising 
alternative, as reported in literature for steroid abuse and in sports doping 
(Cacciatore et al., 2009; Ding, List, Okada, & Kopchick, 2009; Mooney et al., 2008; 
Pinel et al., 2010; Teale, Barton, Driver, & Kay, 2009). Therefore, recently developed 
screening methods were focussed on detection of rbST-dependent biomarkers, 
instead of rbST itself (Ludwig, Smits, Van der Veer, Bremer & Nielen, 2012; Smits, 
Ludwig, Van der Veer, Bremer & Nielen, 2013). A small set of biomarkers was used 
for pinpointing rbST use: insulin-like growth factor 1 (IGF-1), IGF binding protein 2 
(IGFBP2), osteocalcin and rbST-induced antibodies. With the rbST induced 
antibodies as a specific rbST biomarker and the other biomarkers as ST dependent 
markers, a specific protein biomarker profile for hormone abuse in general is 
provided (Ludwig, Smits, Cannizzo & Nielen, 2013). The results obtained with these 
screening methods, however, need to be confirmed, providing absolute proof of the 
identity of the abused compound. Until now only one confirmatographic method for 
detection of rbST in blood samples, using a liquid chromatography-mass 
spectrometry (LC/MS) method, was described (Le Breton, Rochereau-Roulet, Pinel, 
Cesbron & Le Bizec, 2009). This method, however, lacked robustness to enable the 
reliable detection of rbST positive serum samples (personal communication, M. 
Blokland). Therefore, a novel approach is needed, to enable detection of low levels of 
rbST in bovine serum. In human doping control, promising results are obtained for 
detection of traces of peptide hormones by immunoaffinity purification prior to liquid 
chromatography-mass spectrometry (Thomas, Schänzer, Delahaut & Thevis, 2012). 
Therefore, this study will focus on the possibility to combine immunologically based 
affinity purification and chemical confirmation to obtain a new confirmatory method for 
the detection of rbST in bovine serum. 
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3 Materials and Methods 
 
In this chapter first the materials used are specified, including where they can be 
purchased. This will be followed by an explanation of the several methods used in 
the development of this method to pinpoint rbST abuse. As this is a rather technical 
chapter, for clarification, the workflow is schematically presented in Figure 3.2 at the 
end of this chapter. 
 
3.1 Materials 
 
Monsanto rbST standard was obtained from the National Hormone & Peptide 
Program (NHPP) of Dr. Parlow (Torrance, CA, USA). Lactotropin 500 mg single-dose 
syringes were purchased from Centro de Tecnologia (Rio de Janeiro, Brazil). MagSi-
proteinG 1.0 magnetic beads and MagSi-S COOH 1.0 were purchased from 
Magnamedics (Geleen, The Netherlands). Dyna-Mag-2 Magnetic particle 
concentration was purchased by Life Technologies (Bleiswijk, The Netherlands). 
Protein G HP SpinTrap columns were purchased from GE Healthcare (Diegem, 
Belgium). Pierce BCA protein assay was purchased from Thermo Fisher Scientific 
(Rockford, IL, USA). Hydrochloric acid, potassium phosphate, sodium azide, sodium 
chloride, sodium hydroxide, sodium phosphate, Tween-20 and the ultrasonic cleaner 
were purchased from VWR International (Amsterdam, The Netherlands). 
Triethanolamine was supplied by Fisher Scientific (Landsmeer, The Netherlands). N-
hydroxysulfosuccinimide sodium salt (sulfo-NHS) was supplied by Fluka (Steinheim, 
Switzerland). Bovine serum albumine (BSA), trypsin, 
tris(hydroxymethyl)aminomethane, 2-(N-morpholino)ethanesulfonic acid (MES 
hydrate), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), 
iodoacetamide (IAA), dimethyl pimelimidate dihydrochloride (DMP) and DL-
dithiothreitol were purchased from Sigma-Aldrich Chemie (Zwijndrecht, The 
Netherlands). Methanol and acetonitrile were purchased from Biosolve 
(Valkenswaard, The Netherlands). Protein Lobind Tubes (1.5 mL, 2.0 mL) and a table 
centrifuge model 5810R were supplied by Eppendorf (Hamburg, Germany). The 
Jouan GR 20-22 ultracentrifuge was obtained from Jouan (Saint-Herblain, France). 
The Snijder test tube rotator was purchased from Omnilabo International (Breda, The 
Netherlands). The LC-column: Waters BEH C18 (2.1 x 100 mm, 1.7 μm) and Waters 
Xevo TQS were obtained from Waters (Etten-Leur, The Netherlands). The isotopic 
labelled peptides were obtained from Bachem (Bubendorf, Switzerland). Zymark 
TurboVap was purchased from Biotage (Uppsala, Sweden). 
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3.2 Methods 
 
3.2.1 Serum samples 
 
To obtain serum samples of a treated animal, one 3 year old dairy cow was treated 
twice with subcutaneous injections of 500 mg Lactotropin. This treatment took place 
in a combined steroid-rbST-treatment schedule, consisting of two subcutaneous 
injections of each compound, administered in a weekly fashion.  This combination 
was made for ethical reasons: to obtain sample material of the different treatments, 
which are unlikely to interfere with each other, from a single animal. After each 
treatment, a wash out of 2 weeks was taken into account.  Treatments were with 
norclostebol acetaat, Lactotropin and clobetasolpropionate respectively, as shown in 
Figure 3.1. 
 
 
Figure 3.1: Outline of the animal study 
During the treatment period, blood samples were collected daily till one week after 
the last administration. After blood collection, the blood sample was placed at room 
temperature for 4 h to coagulate and subsequently centrifuged for 10 min at 3.000g. 
Serum was collected and stored at -80 ºC until further use.  
The experimental procedure was authorized by the ethical committee of ID-DLO in 
Lelystad, The Netherlands. 
 
3.2.2 Preparation of polyclonal antiserum 
 
Preparation of the polyclonal antiserum against Elanco rbST was described before by 
Heutmekers, Bremer, Haasnoot & Nielen (2007). Briefly, a New Zealand White rabbit 
(No. 58) was immunised with Elanco rbST in 1989 at the Centre for Small Laboratory 
Animals in Wageningen, the Netherlands, and blood was obtained during the total 
treatment period and serum was collected. The individual collected sera showed 
similar antibody titers specific for rbST using surface plasmon resonance with rbST 
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coated on a chip. Therefore, a mixture of the sera, pre-immune serum excluded, was 
stored as such for further use.  
 
3.2.3 Purification of polyclonal antiserum 
 
Two different purification steps of the polyclonal antibodies were used prior to bead 
coupling: isolation of the protein fraction by ammonium sulphate precipitation and 
isolation of the antibody fraction (IgG) using protein G. 
For ammonium sulphate precipitation: To concentrate the antibodies from the serum 
and to remove abundant proteins, first the rabbit serum was diluted three times with 
PBS (154 mM NaCl, 5,39 mM Na2HPO4, 1,29 mM KH2PO4, pH 7,4). Then, slowly, 
under constant stirring, an equal amount of saturated ammonium sulphate was 
added. This solution then was left without stirring at room temperature for 30 minutes. 
Subsequently, the solution was ultra-centrifuged for 10 minutes at 10.000g, the 
supernatant was discarded and the pellet was resuspended in PBS to restore the 
starting serum volume. Finally, the protein solution was dialysed against PBS for 24 
hours. The protein concentration was determined by the BCA assay according to the 
manufacturer’s protocol (Piercenet, n.d.). 
For protein G purification, the rabbit serum was added to protein G spin columns and 
the purification protocol according to the manufacturer’s protocol was followed 
(GEHealthcare, n.d.). The protein concentration was determined by the BCA assay 
according to the manufacturer’s protocol (Piercenet, n.d.). 
 
3.2.4 Preparation of magnetic beads 
 
For the coupling of the polyclonal anti-rbST antibodies to magnetic beads, two 
different types of beads were used. First, COOH-magnetic beads were coupled with 
the ammonium sulphate-precipitated polyclonal antibodies and protein G-purified 
polyclonal antibodies, respectively. Second, protein G magnetic beads, where the 
ammonium sulphate precipitated polyclonal antibodies were affinity bound to and 
then cross-linked to obtain a covalent binding. 
 
3.2.4.1 Antibody binding to COOH magnetic beads 
 
Ammonium sulphate-precipitated and protein G-purified antibodies were coupled to 
magnetic COOH beads using a two-step carbodiimide reaction. During the whole 
procedure, beads were concentrated by a magnet (for 3 min) and after removal of the 
supernatant, beads were resuspended by vortexing (for 1 min) and sonication (for 1 
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min), unless mentioned otherwise. For coupling 2 x 109 beads, present in 200 μL of 
bead stock suspension, were used. Therefore, first the stock solution needed to 
acclimatize to room temperature (for 5 min) and be resuspended by constant 
vortexing (for 5 min) and sonication (for 1 min). Beads were then transferred to a 
LoBind tube, concentrated and resuspended in 100 μL of water. This bead 
suspension was concentrated and resuspended in 80 μL of activation buffer (100 mM 
NaH2PO4, pH 6.2). Then 10 μL of Sulfo-NHS (50 mg mL
-1) was added to the beads 
and mixed gently by vortex, followed by addition of 10 μL EDC (50 mg mL-1) and 
gently mixing by vortex. Beads were then incubated for 18 min at room temperature 
under continuous mixing (head over head). After this incubation step, beads were 
concentrated and resuspended in 500 μL of 50 mM MES (pH 5.0). This wash 
procedure then was repeated twice. After the wash procedure, the concentrated 
beads were resuspended in 500 μL of a 100 μg mL-1 ammonium sulphate-purified or 
protein G-purified antibody solution in MES buffer. This bead suspension was then 
incubated for 2 h at room temperature under continuous mixing (head over head). 
Afterwards, beads were concentrated and resuspended in 500 μL of blocking buffer 
(PBS, 0.1% BSA, 0.02% Tween-20 and 0.05% NaN3) and incubated for 30 minutes 
under constant mixing (head over head). After this blocking step, twice a wash 
procedure, where beads were concentrated and resuspended in 500 μL of blocking 
buffer, was carried out. Finally, beads were stored in blocking buffer at 2-8 °C until 
use. Under these storing conditions, beads were stable for over a year. 
 
3.2.4.2 Antibody binding to protein G magnetic beads 
 
The ammonium sulphate-precipitated antibodies were covalently coupled by cross-
linking to protein G-coated magnetic beads according to Careri et al. (2008) with 
slight modifications. Briefly, 200 μL containing 2 x 109 protein G magnetic beads 
were washed with water and then incubated for 4 h with 500 μL of 0.5 mg mL-1 
ammonium sulphate-purified antibody in PBS. Beads were concentrated and washed 
twice with 500 μL of 200 mM triethanolamine pH 8.2. To ensure efficient binding 
between the antibodies and protein G, antibodies were cross-linked to the protein G 
by incubating the beads for 30 minutes under rotation with 500 μL 20 mM DMP in 
200 mM triethylanolamine. After cross-linking, beads were concentrated and 
resuspended in 500 μL 50 mM Tris-HCl pH 5.0 under rotation (15 min). Finally the 
beads were washed three times with PBS and stored in blocking buffer at 2-8°C until 
use. 
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3.2.5 Immunoaffinity extraction of rbST using beads 
 
During the immunoaffinity extraction beads were concentrated by a magnet (for 3 
min) and beads were resuspended by vortex (for 1 min), unless mentioned otherwise. 
For extraction, the antibody-coupled beads first needed to acclimatize to room 
temperature (for 5 min) and then were re-suspended. Fifty microliters of beads were 
transferred to a LoBind tube and concentrated. Concentrated beads were then 
washed by resuspension in 200 μL PBST (PBS, 0,05% v/v Tween-20). Beads were 
concentrated and 1 mL of serum, followed by 4 mL of PBST were added to the 
beads. This mixture was shortly mixed by vortex and incubated for 1 hr at room 
temperature under constant mixing (head over head). Beads were concentrated, the 
supernatant was discarded and beads were then resuspended in 1 mL of PBST. 
Beads were spinned down for some seconds to remove the bead suspension from 
the lid using a table centrifuge and the beads were then concentrated. The 
supernatant was discarded and 50 μL of 200 mM NaOH was added to elute rbST 
from the beads. Beads were resuspended, followed by 5 minutes incubation at room 
temperature without mixing. Then beads were resuspended again and concentrated. 
The supernatant was transferred to a new LoBind tube and 100 μL 1M tris pH 8 was 
added. Samples were stored at -20˚C until sample digestion and clean-up prior to the 
LC-MS/MS measurements. 
 
3.2.6 Sample digestion and clean-up 
 
Before performing the tryptic digest, internal standard solution containing isotope 
labelled bST peptide was added to the bead eluate. This peptide is a replicate of the 
17 amino acids of the N-terminal end of endogenous bST, and therefore only 1 
amino acid different from the rbST. This peptide is labelled by using 6 times C13 and 
4 times N15 resulting in a mass increase of 10. The pH of the obtained suspension 
should be higher than 7.5 before adding 5 μL 45 mM DL-dithiothreitol (DTT). After 
adding DTT the suspension was mixed and incubated for 30 minutes at 37 °C. The 
solution was cooled down to room temperature and 5 μL 0.1 M iodoacetamide was 
added. The solution was mixed by vortex and incubated for 30 minutes at room 
temperature in the dark. The solution was mixed by vortex and subsequently 1 μg 
trypsin for protein digestion was added, mixed by vortex again and incubated 1 hour 
at 37 °C. The digestion was stopped by adding 1 mL 5 % formic acid. To decrease 
possible background signals, to remove salts and to concentrate the peptides specific 
for bST and rbST a solid phase extraction (SPE) was applied. The digest was 
concentrated on a Varian Bond Elut Plexa SPE column (60 mg 3 mL-1). After 
conditioning the column with 2 x 1 mL methanol and 1 mL 5% formic acid in water, 
the sample, was applied onto the column. The column was washed with 1 mL 10% 
acetonitrile and then eluted with 1 mL water/acetonitril/formic acid 25/70/5 (v/v). The 
eluted fraction from the SPE was collected in a polypropylene tube containing 100 µL 
32 
 
DMSO and then evaporated to approximately 100 μL on a Zymark TurboVap at 55°C 
under 10 psi N2. After cooling to room temperature, the sample was transferred to an 
injection vial.   
 
3.2.7 LC-MS/MS 
 
The final extract was analysed by UPLC-MS/MS in multiple reaction monitoring 
(MRM)-mode. The chromatographic separation was performed on a Waters Acquity 
UPLC with a BEH C18 column (2.1 x 100 mm, 1.7 μm), using a gradient containing 
water, acetonitrile and 0.1% formic acid. The Waters Xevo TQS mass spectrometer 
was operated in the positive electrospray ionisation (ESI+)-mass spectrometry 
(MS)/MS positive mode, measuring transition 913,1>774,13 for the rbST peptide of 
interest and transition 888.10>779.13 for the internal standard, resulting in different 
retention times as shown in Figure 3.2. 
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Figure 3.2: Preparation, immunoaffinity and confirmation step for rbST detection in 
serum.  
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4 Results  
 
For the method development of rbST capture prior to the confirmation method, all 
different steps for the method needed to be assessed and optimized. To extract rbST 
from samples, magnetic beads were coupled with a polyclonal antiserum to enable 
immuno-purification. This antibody was chosen for its capacity for binding of rbST as 
well as bST itself (Heutmekers et al., 2007). For the use of these magnetic beads as 
clean-up tool, first, the need of an elution step was studied. The second focus was on 
the antibody orientation on the bead, as orientation could increase the availability of 
antigenic binding places to rbST, thereby increasing the amount rbST captured. 
Then, the matrix was introduced. Optimal dilution factors of the serum needed to be 
determined, as serum is a viscous matrix disabling movement of the beads, but on 
the other hand, high dilution factors decreases the concentration of rbST and could 
lower the amount of rbST captured. Furthermore, the elution conditions were 
optimized for development of the bead based method. Experiments started with 
elution conditions for regeneration use in Surface Plasmon Resonance methods 
(SPR), as obtained from literature (Heutmekers et al., 2007). Then multiple small 
steps were assessed to increase the sensitivity of the method. For this, the 
incubation time and the use of Tween 20 were researched, which then was followed 
by the determination of the sensitivity which can be obtained with the developed 
method. Finally, as a proof of principle, the developed optimized method was used 
for rbST confirmation in a selection of incurred serum samples, obtained from an 
animal experiment.  
 
4.1 Determining necessity of rbST elution from the beads 
 
As a start, the necessity of elution of rbST and bST from the beads was assessed. 
An on-bead tryptic digestion was compared with a digestion of (r)bST eluted from the 
beads. Elution conditions were set at 50 mM NaOH as described by Heutmekers et 
al. (2007) and COOH beads with ammonium sulphate-precipitated antibodies were 
used for this comparison. Two different buffers were chosen, tris buffer as being 
trypsin compatible and PBS as commonly used in immunoassays and affinity 
purifications. All obtained samples were prepared for and measured with LC-MS/MS. 
This resulted in a higher rbST yield when PBS was used. On bead digestion resulted 
in a brownish solution, not suitable for injection on the LC-MS/MS. Optimization of 
buffer and digestion type therefore led to use of PBS buffer in combination with an 
elution step to obtain rbST from samples. 
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4.2 Optimization of rbST capture efficiency by antibody orientation on 
the bead  
 
As orientation of the antibodies bound to the beads and antibody purity might be of 
influence on the clean-up performance of the magnetic beads, different coupling 
strategies were compared (Trilling, Beekwilder & Zuilhof, 2013). For comparison, one 
batch of COOH magnetic beads coupled with ammonium sulphate-precipitated 
antibody, one batch with protein G-purified antibody and as a third batch the 
ammonium sulphate precipitated-antibody coupled to protein G magnetic beads were 
used. Solutions of 0, 10 and 100 ng rbST in 200 μL PBS were incubated with all 
three magnetic bead types. Peak areas were then measured by LC-MS/MS. This led 
to differences in capturing rbST from the solution as can be seen in Figure 4.1.  
 
 
Figure 4.1: Comparison of the three different bead batches prepared, COOH 
magnetic beads coupled with ammonium sulphate-precipitated antibody No. 58 
(▲),COOH magnetic beads coupled with protein G-purified antibody No. 58 (■) and 
protein G magnetic beads with antibody No. 58 (♦).Differently from the other 
measurements, rbST was measured with the nanotyle LC-MS/MS. 
 
The ammonium sulphate-precipitated antibodies coupled to COOH beads gave worst 
results at 10 ng spike level, but best results at the 100 ng spike level. As at this point 
no internal standard was added yet, and the 10 ng spike level gave small peaks 
which were difficult interpretable, results from the 100 ng spike level were decisive, 
as obtained graphs were better interpretable. Therefore, the ammonium sulphate-
precipitated antibodies coupled to COOH beads were chosen as optimal beads for 
capturing rbST. Moreover, they are preferred from a practical point of view, as their 
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purification and coupling strategy is very easy to perform. Further optimization of the 
method is therefore, performed with the COOH beads coupled with ammonium 
sulphate-precipitated antibodies. 
 
4.3 Capturing rbST from serum samples 
 
The objective of this method is to measure rbST in serum samples of rbST-treated 
dairy cows. Dilution factors up to ten-times and different elution conditions, from 50 
mM NaOH up to 200 mM NaOH, were tested. Figure 4.2 shows the effect of the 
strengths of the elution conditions. Each time, 200 μL final sample volume was used. 
Optimal results, i.e. highest rbST yields, with all serum dilutions were obtained with 
more harsh conditions for elution, 200 mM NaOH. Moreover, with increasing the 
dilution factor, more rbST was measured as can be seen in Figure 4.2. As a ten times 
serum dilution gives the best results, practical problems like tube size in combination 
with a suitable magnet are expected.  
 
 
Figure 4.2: Determination of optimal serum dilution with 50 mM NaOH (♦), 75 mM 
NaOH (■), 100 mM NaOH (▲) and 200 mM NaOH (●) as elution conditions. 
Therefore, based on these results, the five-times serum dilution was chosen to 
enable working with larger serum volumes.  
 
  
38 
 
4.4 Sensitivity increment of the method: time and buffer adjustment 
 
To increase the sensitivity of the method, extending incubation times of rbST in 
serum with the magnetic beads was tested. This did not lead to a sensitivity 
increment as it showed that free rbST binds rapidly to the antibodies, reaching 
equilibrium almost directly after rbST addition (data not shown). A small adjustment 
of adding Tween-20 to the dilution buffer resulted in a small sensitivity increment, due 
to a decrease in background signal. Until now only small serum volumes were spiked 
with rbST. As concentrations are suspected to be lower than 30 ng mL-1 as described 
by Schams et al. (1991), or even lower than 10 ng mL-1 as shown by Le Breton et al. 
(2009), enough rbST can only be captured from serum samples, with increased 
serum sample volume. To determine the sensitivity of the method with the use of 1 
mL of serum, a calibration curve was made wherein 1 mL of bovine serum of day 11 
of the animal experiment, prior to treatment, was spiked with respectively 0, 5, 10 and 
20 ng rbST. This resulted in a calibration curve as shown in Figure 4.3. Where the 5 
ng mL-1 clearly gave a response factor for rbST to the internal standard, showing this 
method is sensitive enough to measure below the required 10 ng mL-1. 
 
 
Figure 4.3: Calibration curve obtained by fortifying a serum sample, obtaining results 
for 3 different concentration of rbST. 
 
  
39 
 
4.5 Determination of rbST in serum of treated bovines 
 
With the sensitivity shown in the above experiment,  the method should be sensitive 
enough to enable rbST detection in samples obtained from rbST-treated cows. 
Therefore, as a proof of principle, a small selection of serum samples of the formerly 
executed animal experiment was selected. In total 6 sera were selected (Figure 3.1): 
the day of the first treatment (day 28), day 30, day 34, the day of the second 
treatment (day 35), day 37 and finally three weeks after the second treatment (day 
56). In Figure 4.4, the 20 ng mL-1 spiked serum sample from the calibration curve is 
compared with the serum sample obtained at day 34, the 6th day after injection and 
the serum sample taken after the treatment period. The spiked serum sample and the 
serum sample obtained after injection clearly show a rbST peak, the serum sample 
taken more than 3 weeks after the last rbST treatment, provides no rbST peak, as 
expected due to the short half-life of rbST in serum. 
 
 
Figure 4.4: Comparison between sera from one dairy cow. First, 1 mL serum spiked 
with 20 ng rbST, second, 1 mL serum 6 days after rbST treatment and third serum 
obtained after the treatment period. 
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Table 4.1, shows the results from the other sera from the animal experiment. RbST 
was first found at day 34, 6 days after the first injection and then in all the following 
serum samples measured, with exception of the serum sample taken after the 
treatment period as described above.  
 
Table 4.1: rbST concentrations found in the serum samples selected after rbST 
treatment of a dairy bovine cow.  
day 
Relative signal intensity 
(rbST/internal standard) Concentration (ng mL-1) 
28 0,008 - 
30 0,011 - 
34 0,052 4,7 
35 0,029 1,8 
37 0,026 1,5 
56 0 - 
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5 Discussion 
 
The hypothesis in the introduction of this report states that “detection and 
confirmation of rbST in serum will be enabled” suggests that a confirmatory method 
for detection of rbST in serum didn’t exist up to now.  Le Breton et al. (2009) 
however, already published an article presenting a method for the detection of rbST 
in serum of dairy cattle, including measurements in incurred samples. As a first step 
for rbST measurements in serum of dairy cattle, attempts for implementing this 
method were made. Unfortunately, we were unable to measure rbST using this 
technique. Subsequently, results from incurred serum samples of an animal 
experiment were required, and therefore sent to the laboratory where this 
confirmatory method was developed.  No results were obtained for the serum 
samples sent. Moreover the developers themselves weren’t able anymore, for over a 
year, to detect rbST with this technique (Pinel G., personal communications, April 
25th, 2013). When taking a closer look to their method, some peculiar steps are made 
which might explain the inability to detect rbST. For instance, serum is pre-treated by 
ammonium sulphate precipitation 45%. This ammonium sulphate precipitation step is 
known for the removal of high abundant proteins (Colantonio, Dunkinson, 
Bovenkamp & Van Eyk, 2005). Le Breton et al. (2009) used the obtained precipitate 
for rbST detection, most likely supressing the rbST signal by the high concentration 
of abundant proteins, but possibly also losing rbST as this might not all precipitate. 
Furthermore, the choice of using SPE C4 on an intact rbST protein seems not 
beneficial, as SPE C4 columns are used to extract non-polar compounds (Magery-
Nagel, n.d.). Additionally, after trypsin digestion the peptide of interest isn’t stabilized. 
With these three actions only traces of your protein of interest will be available for 
detection. Possibly this explains the lack in sensitivity of this method. As this existing 
method isn’t working, this study was focussed on developing a new method which 
captures rbST. 
The rbST capture method is immunoaffinity based, therewith using all kinds of pH 
neutral physiological buffers.  In contrast, the LC-MS/MS method is chemically 
based, mainly using organic solvents and water. To combine both techniques 
seemed powerful and promising, but due to incompatible buffers and solvents it was 
also a great challenge.   
One of these challenges was finding the balance between the amount of sample, 
dilution factor and digestion step. These parts all interfere with the LC-MS/MS 
background signal, which will suppress the rbST signal. In view of the low mass 
concentrations to be detected, each individual step needed to be optimized and 
instrument performance  was used at its limits.  For instance, rbST content in serum 
of treated animals will be in the low ng mL-1 range. Therefore, enough serum is 
needed to enable LC-MS/MS measurements. This, however,  also counteracts as 
with more concentrated serum, which is a complex matrix, more background signal 
will occur due to aspecific binding of serum proteins to the magnetic beads, which 
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subsequently will suppress the rbST signal. This could be solved by using a higher 
serum dilution. This, however, runs into practical problems like the need for bigger 
tubes and magnets, and lower capture abilities, as antibody binding is dependent on 
the concentration and not on the absolute amount available. As an alternative, on-
bead digestion was tried. After on-bead tryptic digestion the solution looked dirty and 
a decrease in signal intensity on the LC-MS/MS due to signal suppression was also 
expected with this treatment. Therefore, removal of the beads with a magnet and also 
the SPE clean-up step were necessary before LC-MS/MS measurement, abating all 
the advantages of on bead digestion over the rbST elution step. Moreover, it was 
expected that the signal suppression would increase in samples of serum so the use 
of on-beads digestion was not further assessed.  
 
Antibody orientation on the bead 
For optimization of the immunoaffinity step, different coupling strategies for steering 
antibody orientation were assessed. Theoretically, when the rbST has optimal access 
to the antigen binding sites of the antibodies, higher rbST yields can be expected. 
This can be achieved with the right antibody orientation on the magnetic bead 
surface. Protein G magnetic beads were therefore expected to give optimal results. 
As antibodies will bind with their heavy chain to the protein G on the bead, their 
antigenic binding sites will be oriented away from the beads, giving optimal access to 
the rbST available in solution. The different bead types tested, however, did not 
confirm this theory. Comparing all bead types, variation in measured peak area is 
seen at all tested spike levels, but also when PBS was not spiked with rbST. 
Subsequently, the results obtained show a similar trend in binding capacity for all 
three magnetic bead batches. But none of the three magnetic bead batches 
displayed an impressing performance in comparison to the others. For the two 
batches made with COOH magnetic beads, random orientation was expected, 
consequently offering lesser antigenic binding sites, if taken a fixed amount of 
antibodies (Trilling et al., 2013). However, the final absolute amount of antibodies 
coupled is not clear. Therefore it is possible that more antibodies are coupled, 
offering similar amounts of free antigenic binding sites as with the protein G magnetic 
beads. Moreover, orientation of the antibodies themselves with the heavy chain 
towards the round surface of the COOH magnetic bead due to steric hindrens is also 
a possibility (Iafisco et al., 2012). Therefore, it is concluded that the different coupling 
procedures did not result in significant differences on the capacity of the antibodies 
for rbST.  
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rbST capture  
Serum samples are more complex matrixes in comparison with the buffers, likely to 
give high background signals. Serum is also more viscous than the previous used 
buffer, hindering the beads from moving through the sample. Therefore, for the 
applicability of the beads in serum samples, dilution factors of serum needed to be 
determined and also elution circumstances needed to be optimized. Dilution factors 
indeed turned out to be of great importance. Low dilution factors led, as suspected, to 
clotting of the beads and signal suppression due to high background signals. 
Furthermore, the previously used elution step, 50 mM NaOH as obtained from 
Heutmekers et al. (2007), was used as regeneration step for SPR chips. These chips 
however, should be reused after regeneration. Therefore, this always requires the 
mildest regeneration conditions, removing the compound bound, but leaving the chip 
and the coated antibody intact. These mild circumstances are not needed for the 
magnetic beads as these are for single use and aiming at high rbST yield. Therefore 
harsher elution conditions could be examined and in fact proved to be more efficient. 
RbST capture from incurred serum samples showed to be successful, proving the 
strength of the combination of an immunoaffinity step prior to LC-MS/MS 
confirmation. The results found are in accordance with results found by Schams et al. 
(1991), who saw a first increase seven days after the first injection. The most intense 
rbST peak was displayed at this day, where a rbST concentration of 4,7 ng mL-1 was 
found. A decrease in concentration to 1,8 ng mL-1 was seen at the following day, day 
35. This was also the day of the second injection. At day 37, two days after the 
second injection, a concentration of 1,5 ng mL-1 was found. When the second day 
after the first and second injection were compared, day 28 and 35, day 35 clearly 
shows a higher rbST concentration than found at day 28. Probably, this is rbST from 
the first administration which is still circulating in the blood, as results from day 28 
clearly showed that it is not possible yet to detect rbST right after its administration. 
Moreover, a similar effect was  seen in the second day after injection, respectively 
day 30 and 37, where day 37 displayed an rbST signal compared to no signal at day 
30. So far, no further serum samples from the week after the second injection were 
measured. But, if again the highest rbST concentration occurs at day 6 after injection, 
as is similar to the 7 days described by Schams et al. (1991), rbST will be detectable 
at almost all or all days from the second injection on. Representing the use of the 
slow releasing formulae as the short half-life of rbST is 15 to 30 minutes in blood 
circulation (Bauman & Vernon, 1993). Furthermore, rbST is not detectable anymore 
at day 56, three weeks after the last injection. These preliminary results of serum 
samples obtained for an rbST-treated cow are a proof of principle for the developed 
method. However, further research for development of this method in the future 
should be focussing on sensitivity and robustness of the method, aiming at a method 
usable in national and international rbST controlling programmes. 
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Applicability of this new technique in other research fields 
This method not only shows the possibilities for rbST detection in serum, but a better 
understanding of the pros and cons of this technique makes it applicable for many 
research fields. In case of environmental science there is a wide range of 
applications where this technique would suit. For instance, currently, the problem of 
the “plastic soup” is getting under the attention of the broad public. One possible 
problem due to this plastic soup is Bisphenol A (BPA), an endocrine disruptor, which 
migrates from these plastics. It is shown that at very low concentrations BPA already 
acts as functional estrogen (Mansilha et al., 2013). This probably will influence 
ecosystems and consequently human health. As BPA is not very soluble, it will manly 
bind to sediments and soil in the water. When research will be focussed on 
determining BPA in water, the developed technique, using antibodies directed 
against BPA could be used. With immunoaffinity purification, BPA, present in low 
concentrations in the water, could be captured and concentrated to obtain proper 
amounts enabling confirmatory measurement. Moreover, as the magnetic beads in 
this method show applicability for complex matrices, these can be used to capture 
BPA from sediments and soil. Additionally, also the appearance in ecosystems could 
be studied by using this technique to measure BPA content in different species.   
Focussing on endocrine disruptors, they are getting more and more of a problem in 
the environment. Contraceptive drugs entering surface waters via the wastewaters 
are found in aquatic environments. Particularly 17α-ethinylestradiol then acts as an 
endocrine disruptor in natural ecosystems even in low concentrations (Souza, 
Hallgren, Balseiro & Hansson, 2013). Therefore, the acceptable environmental 
concentration has been lowered. As one of the options for reducing this problem is 
wastewater treatment, detection methods are needed to measure effectiveness of the 
applied treatment steps. This requires high sensitivity in complex matrixes, which 
currently is a challenge according to Petrie, McAdam, Scrimshaw, Lester and Carmell 
(2013). Also here the method developed in the present study could be of interest.  
 
rbST and the environment 
rbST as hormonal compound is normally not entering the surface water. However, as 
the use of rbST at salmon aquacultures is daily practice in some companies, and 
high amounts are administered and found back in these salmons (Rochereau-Roulet 
et al., 2013) it can be questioned  whether rbST is also spoiled into the water and can 
enter wastewater facilities, and next the environment, exhibiting its hormonal action.  
Furthermore, literature about environmental impact of rbST is mainly focussing on the 
reduction in GHG emissions as mentioned in paragraph 2.3, so positive 
environmental features of rbST use are highlighted in literature but not the downside. 
For instance, environmental impact due to the increased use of antibiotics is not 
mentioned.  Its use was already described in paragraph 2.4.2 “animal health”. The 
antibiotics used are excreted and then can be found in different environmental 
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compartments due to drainage of surface and runoff and release from wastewater 
treatment plants. The antibiotics entering the environment can have impact on 
environmental communities in aquatic ecosystems showing significant associations 
for antibiotic resistance genes (Heurta et al., 2013).  
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Conclusion 
 
A novel immunoaffinity magnetic bead based approach for capturing rbST followed 
by LC-MS/MS measurement was developed. No extensive purification step was 
needed for the rbST antibodies as magnetic beads coupled with ammonium sulphate 
precipitated antibodies already made it possible to detect rbST in serum in 
concentrations far below the required 10 ng mL-1. Due to the high sensitivity 
obtained, a detection window possibly up to the total treatment period can be 
reached, as presented with the selection of serum samples from the rbST treated 
dairy cow. Furthermore, a highest concentration of approximately 5 ng mL-1 was 
found the 6th day after rbST administration and rbST of the first administration was 
detectable in the blood circulation at the moment of the following administration. The 
presented preliminary results therefore clearly show the high potential of this 
developed confirmatory method to be adequate for pinpointing rbST abuse. 
  
48 
 
  
49 
 
Recommendations 
 
As this research is a start in obtaining a confirmatory method, many 
recommendations can be made.  
First, the developed assay still needs further improvement, as the principle is 
proofed, but not enough knowledge is obtained yet for implementation in controlling 
programs. For this sensitivity, inclusive Limit of detections and Limit of Quantification, 
and precision need to be determined according to standard operational procedures 
described by RIKILT. Moreover, also repeatability of the assay needs to be 
researched by inter-assay and intra-assay variation.  
The method currently focusses on the detection of a single peptide. For 
unambiguous identification this might not be sufficient. Currently, there are no 
international guidelines for confirmation of the presence of banned proteins. The 
elimination kinetics of rbST in dairy cows can be researched and its detection window 
in incurred samples can be determined. This will further substantiate the value of the 
developed method for monitoring programs.  
Second, as obtaining serum is invasive for dairy cows, a future aim should be to 
transfer this method to milk. Obtaining milk is non-invasive, and even tank milk can 
be used for this purpose. The rbST concentration in milk is much lower than in 
serum, suspected concentration is around 1 ng mL-1. Detection of rbST in milk 
therefore requires a more sensitive method which should be developed.  
Third, for acquiring a higher sensitivity to enable method development for a 
confirmatory method in milk, but also to obtain more sensitive results in the serum 
confirmatory method, awareness of emerging techniques is required and should be 
brought into practice. For instance in the immunoaffinity field, a novel approach to 
replace magnetic beads is offered, MSIA, immunoaffinity tips which should provide a 
higher yield than magnetic beads. Or in the MS field, developments in nano-scale, 
like the nanotyle UPLC-MS are developments which should provide higher 
sensitivities. 
Fourth, the strength of the combination of the two expertise fields should be brought 
to the attention of researchers. As they provide many opportunities in all kind of 
research fields, like for instance the field of environmental sciences.   
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Appendix I 
 
Symbols for amino acids (Stryer, 1988).  
A Ala Alanine 
B Asx Asparagine or aspartic acid 
C Cys Cysteine 
D Asp Aspartic acid 
E Glu Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methione 
N Asn Aspargine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W Trp Tryptophan 
Y Tyr Tyrosine 
Z Glx Glutamine or glutamic acid 
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